Insight into chromatin therapies for breast cancer could aid personalized medicine

(Boston University School of Medicine) Most traditional chemotherapy for cancer has dangerous side effects, but new research is finding ways to develop 'targeted agents' that reduce the side effects and are better tailored to individual patient needs. While these innovations are exciting, a new study shows how certain cancer inhibitors need to be examined more carefully to better understand fine-grained effects and counter-effects, which could yield more effective and safer therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Authors: Jaiswal K, Hull M, Furniss AL, Doyle R, Gayou N, Bayliss E Abstract Background: Timely detection and treatment of breast cancer is important in optimizing survival and minimizing recurrence. Given disparities in breast cancer outcomes based on socioeconomic status, we examined time to diagnosis and treatment in a safety-net hospital. Methods: We conducted a retrospective review of all patients with breast cancer diagnosed between July 1, 2010, and June 30, 2012 (N=120). We limited our analytic sample to patients with nonrecurrent, primary stage 0-III breast cancer (N=105) and determined intervals from pres...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
This study aimed to increase its half-life and anticancer activity; minimize its side effects; and prolong its drug release by intercalating of DAC in biodegradable NaCa-LDH (DAC-LDH). Results from the intercalation process show that NaCa-LDH is able to intercalate DAC with a simple procedure and with a good drug loading (38% w/w) through a one pot reaction. The DAC shows a sustained and pH-sensitive release, and the release rate of DAC from DAC-LDH at pH 7.4 is remarkably lower than that at pH 6.0 due to its different release mechanisms. In the latter case, the release was not complete at 24 h. We show that DAC-LDH ...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
This study included 140 primary breast cancer patients with stage I-III. Serum samples were collected before surgery and stored at -80 degrees. CD44 and ALDH1A1 were measured by chemiluminescent assay.Results: High serum CD44 levels (≥ 417.4 ng/mL) were correlated with postmenopausal status (P = 0.006), estrogen receptor negativity (P = 0.025), progesterone receptor negativity (P = 0.002) and adjuvant chemotherapy (P = 0.003). The mean serum CD44 levels of luminal group (406.4 ± 68.3 ng/mL) were significantly lower than triple negative group (506.8 ± 175.5 ng/mL) (P
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
The 21-gene recurrence score (RS) is increasingly being used for patients with early stage, hormone receptor-positive, Her-2-negative breast cancer. However, these results are largely from populations with infiltrating ductal carcinoma (IDC). The clinical value of RS testing in mucinous carcinoma has not been well investigated. Pure mucinous breast cancer (PMBC) and paired pure IDC patients who underwent 21-gene RS were retrospectively reviewed and matched with tumor stage and molecular subtype. Clinic-pathological factors, treatment strategies, and RS distribution were compared between the PMBC and IDC patients. A total o...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Objectives: To investigate the effect of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer in terms of pCR and cardiotoxicity.Methods: We systematically searched Pubmed, Embase, Cochrane and SinoMed databases from inception until 1 July 2017 for relevant articles of randomized controlled studies. After identified all relevant studies that reported the concurrent use of trastuzumab and anthracycline-based NAC for HER2-positive locally advanced breast cancer, five eligible randomized studies were extracted relevant data and assessed for design and quality...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Contributor : David VenetSeries Type : Expression profiling by array ; Third-party reanalysisOrganism : Homo sapiensBackground: Numerous studies have focused on the PI3K/AKT/mTOR pathway in estrogen receptor positive (ER) breast cancer (BC), as a linear signal transduction pathway and reported its association with worse clinical outcomes. To gain better insight into the relative contribution of each of the signalling pathways which lie downstream to PI3K (namely AKT and mTOR) to BC outcomes, we have developed a novel in silico approach which assessed the activation of each of these signalling pathways separately.Methods: B...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Third-party reanalysis Homo sapiens Source Type: research
Publication date: Available online 13 December 2018Source: Journal of Geriatric OncologyAuthor(s): Andrea Sitlinger, Rebecca A. Shelby, Alyssa N. Van Denburg, Heidi White, Sarah N. Edmond, Paul K. Marcom, Hayden B. Bosworth, Francis J. Keefe, Gretchen G. KimmickAbstractObjectiveTo explore the impact of symptoms on physical function in women on adjuvant endocrine therapy for breast cancer.MethodsEligible women were postmenopausal, had hormone receptor positive, stage I-IIIA breast cancer, completed surgery, chemotherapy, radiation, and on adjuvant endocrine therapy. At a routine follow-up visit, women (N = 107) complete...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
ConclusionThese findings suggested a possible application of PSVII in combination with chemotherapy and/or as neo-adjuvant therapy in the treatment of MDR breast cancer.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer, Published online: 13 December 2018; doi:10.1038/s41388-018-0624-2Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
ConclusionThe present study showed that whole breast IMRT and HypoRT-VMAT are feasible and well tolerated in early-stage BC elderly patients and that HypoRT-VMAT is affected by lower risk of acute and late RT-related side effects.
Source: La Radiologia Medica - Category: Radiology Source Type: research
More News: Boston University | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Study